UBC drug formulation receives $1.1 million for clinical development as HIV treatment

June 05, 2012

A drug delivery system developed through the University of British Columbia's Neglected Global Diseases Initiative and licensed to iCo Therapeutics Inc. will receive $1.1 million from the National Research Council of Canada (NRC) for clinical development as a treatment for HIV patients.

The oral drug delivery system of Amphotericin B (Amp B) was originally developed by UBC Pharmaceutical Sciences Profs. Kishor and Ellen Wasan to address challenges associated with existing formulations in treating individuals with visceral leishmaniasis in the developing world.

Recent studies have shown that Oral Amp B can enhance the efficacy of existing HIV therapies such as highly active anti-retroviral therapy (HAART).

While HAART has been successful in managing and stabilizing HIV in patients, the virus can persist by slowly replicating in tissue and blood. These long-lived HIV reservoirs enable long-term persistence of the infection and constitute a major roadblock to the complete eradication of HIV.

Amp B has now been shown to be efficient in "flushing" the virus from the reservoirs and enhancing the effectiveness of existing therapies.

"We are excited about the potential that oral Amp B may have as a treatment for HIV and thank the National Research Council of Canada and iCo Therapeutics for supporting this important technology," says Kishor Wasan, professor and associate dean of research and graduate studies in the UBC Faculty of Pharmaceutical Sciences. "This funding represents a significant leap forward in the clinical development of the oral formulation of Amp B."

"The development of the Oral Amp B technology has profound implications in the quest to find a cure for HIV," says Andrew Rae, president and CEO of iCo Therapeutics. "We are looking forward to collaborating with UBC and NRC-IRAP on this program and the continued development of the Oral Amp B system."
-end-
BACKGROUND

Oral Amp B as HIV treatment

The $1.1-million support is provided via the NRC Industrial Research Assistance Program, which is a part of the Canadian HIV Vaccine Initiative's Canadian HIV Technology Development Program (CHTD). The Canadian HIV Vaccine Initiative (CHVI) is a joint program of the Government of Canada and the Bill & Melinda Gates Foundation.

Vancouver-based iCo Therapeutics Inc. focuses on reformulating medications with a clinical history for new and expanded indications.

The Neglected Global Diseases Initiative at UBC (NGDI-UBC) brings together the technical expertise and perspectives of a variety of disciplines at UBC - including bench science, pharmaceutical and health research, business, social policy, and law - to develop interventions for neglected global diseases and ensure their delivery to those in need. For more information, visit http://www.ngdi.ubc.ca.

For more information on Oral Amp B and the NGDI, visit http://www.publicaffairs.ubc.ca/?p=15073 and http://ngdi.ubc.ca.

University of British Columbia

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.